Does the media favor DBVT or DYN?

In the previous week, Dyne Therapeutics had 7 more articles in the media than DBV Technologies. MarketBeat recorded 10 mentions for Dyne Therapeutics and 3 mentions for DBV Technologies. Dyne Therapeutics' average media sentiment score of 0.52 beat DBV Technologies' score of 0.47 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CPRX or DBVT?

In the previous week, Catalyst Pharmaceuticals and Catalyst Pharmaceuticals both had 3 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat DBV Technologies' score of 0.47 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DBVT or BEAM?

In the previous week, Beam Therapeutics had 10 more articles in the media than DBV Technologies. MarketBeat recorded 13 mentions for Beam Therapeutics and 3 mentions for DBV Technologies. Beam Therapeutics' average media sentiment score of 0.50 beat DBV Technologies' score of 0.47 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DBVT or RCUS?

In the previous week, Arcus Biosciences had 6 more articles in the media than DBV Technologies. MarketBeat recorded 9 mentions for Arcus Biosciences and 3 mentions for DBV Technologies. Arcus Biosciences' average media sentiment score of 1.15 beat DBV Technologies' score of 0.47 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcus Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RLAY or DBVT?

In the previous week, Relay Therapeutics had 9 more articles in the media than DBV Technologies. MarketBeat recorded 12 mentions for Relay Therapeutics and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.47 beat Relay Therapeutics' score of 0.46 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

DBV Technologies (DBVT) Competitors

$15.98 0.00 (0.00%)

As of 09:36 AM Eastern

Compare

DBVT vs. DYN, CPRX, BEAM, RCUS, and RLAY

Should you buy DBV Technologies stock or one of its competitors? MarketBeat compares DBV Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DBV Technologies include Dyne Therapeutics (DYN), Catalyst Pharmaceuticals (CPRX), Beam Therapeutics (BEAM), Arcus Biosciences (RCUS), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry.

How does DBV Technologies compare to Dyne Therapeutics?

DBV Technologies (NASDAQ:DBVT) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

DBV Technologies currently has a consensus target price of $48.50, suggesting a potential upside of 203.50%. Dyne Therapeutics has a consensus target price of $34.17, suggesting a potential upside of 45.66%. Given DBV Technologies' higher probable upside, research analysts plainly believe DBV Technologies is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Dyne Therapeutics had 7 more articles in the media than DBV Technologies. MarketBeat recorded 10 mentions for Dyne Therapeutics and 3 mentions for DBV Technologies. Dyne Therapeutics' average media sentiment score of 0.52 beat DBV Technologies' score of 0.47 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyne Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Dyne Therapeutics' return on equity of -58.28% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Dyne Therapeutics	N/A	-58.28%	-46.77%

DBV Technologies has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	167.76	-$146.95M	-$4.46	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

DBV Technologies has a beta of -0.95, indicating that its stock price is 195% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

Summary

Dyne Therapeutics beats DBV Technologies on 12 of the 16 factors compared between the two stocks.

How does DBV Technologies compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and DBV Technologies (NASDAQ:DBVT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to DBV Technologies' net margin of -2,895.37%. Catalyst Pharmaceuticals' return on equity of 35.76% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

Catalyst Pharmaceuticals presently has a consensus target price of $32.00, indicating a potential upside of 1.60%. DBV Technologies has a consensus target price of $48.50, indicating a potential upside of 203.50%. Given DBV Technologies' stronger consensus rating and higher possible upside, analysts plainly believe DBV Technologies is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Catalyst Pharmaceuticals and Catalyst Pharmaceuticals both had 3 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat DBV Technologies' score of 0.47 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Catalyst Pharmaceuticals has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.55	$214.33M	$1.74	18.10
DBV Technologies	$5.64M	167.76	-$146.95M	-$4.46	N/A

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Catalyst Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, meaning that its share price is 195% less volatile than the broader market.

Summary

Catalyst Pharmaceuticals beats DBV Technologies on 12 of the 16 factors compared between the two stocks.

How does DBV Technologies compare to Beam Therapeutics?

DBV Technologies (NASDAQ:DBVT) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 203.50%. Beam Therapeutics has a consensus target price of $46.85, suggesting a potential upside of 53.78%. Given DBV Technologies' higher possible upside, equities research analysts plainly believe DBV Technologies is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Beam Therapeutics has higher revenue and earnings than DBV Technologies. Beam Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	167.76	-$146.95M	-$4.46	N/A
Beam Therapeutics	$139.74M	22.43	-$79.99M	-$0.68	N/A

Beam Therapeutics has a net margin of -39.66% compared to DBV Technologies' net margin of -2,895.37%. Beam Therapeutics' return on equity of -29.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

DBV Technologies has a beta of -0.95, suggesting that its share price is 195% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market.

In the previous week, Beam Therapeutics had 10 more articles in the media than DBV Technologies. MarketBeat recorded 13 mentions for Beam Therapeutics and 3 mentions for DBV Technologies. Beam Therapeutics' average media sentiment score of 0.50 beat DBV Technologies' score of 0.47 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Beam Therapeutics beats DBV Technologies on 13 of the 16 factors compared between the two stocks.

How does DBV Technologies compare to Arcus Biosciences?

DBV Technologies (NASDAQ:DBVT) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Arcus Biosciences has a net margin of -156.36% compared to DBV Technologies' net margin of -2,895.37%. Arcus Biosciences' return on equity of -68.97% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

DBV Technologies currently has a consensus target price of $48.50, indicating a potential upside of 203.50%. Arcus Biosciences has a consensus target price of $35.10, indicating a potential upside of 23.96%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts plainly believe DBV Technologies is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Arcus Biosciences had 6 more articles in the media than DBV Technologies. MarketBeat recorded 9 mentions for Arcus Biosciences and 3 mentions for DBV Technologies. Arcus Biosciences' average media sentiment score of 1.15 beat DBV Technologies' score of 0.47 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DBV Technologies has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	167.76	-$146.95M	-$4.46	N/A
Arcus Biosciences	$247M	14.42	-$353M	-$3.18	N/A

DBV Technologies has a beta of -0.95, suggesting that its share price is 195% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

Summary

Arcus Biosciences beats DBV Technologies on 11 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and DBV Technologies (NASDAQ:DBVT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Relay Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Relay Therapeutics' return on equity of -43.94% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

In the previous week, Relay Therapeutics had 9 more articles in the media than DBV Technologies. MarketBeat recorded 12 mentions for Relay Therapeutics and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.47 beat Relay Therapeutics' score of 0.46 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 1.1% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

DBV Technologies has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	235.25	-$276.48M	-$1.57	N/A
DBV Technologies	$5.64M	167.76	-$146.95M	-$4.46	N/A

Relay Therapeutics has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, suggesting that its share price is 195% less volatile than the broader market.

Relay Therapeutics currently has a consensus target price of $23.73, indicating a potential upside of 25.89%. DBV Technologies has a consensus target price of $48.50, indicating a potential upside of 203.50%. Given DBV Technologies' higher probable upside, analysts plainly believe DBV Technologies is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Relay Therapeutics beats DBV Technologies on 13 of the 17 factors compared between the two stocks.

Get DBV Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DBVT vs. The Competition

Export

Metric	DBV Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$946.18M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-3.58	20.85	27.10	24.26
Price / Sales	167.76	314.01	588.85	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	3.80	8.49	10.85	6.29
Net Income	-$146.95M	$23.83M	$3.58B	$330.66M
7 Day Performance	-7.90%	-3.56%	-2.12%	-1.35%
1 Month Performance	-8.27%	6.31%	3.27%	-0.64%
1 Year Performance	51.10%	48.30%	26.33%	19.08%

DBV Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DBVT DBV Technologies	3.8799 of 5 stars	$15.98 flat	$48.50 +203.5%	+48.0%	$946.18M	$5.64M	N/A	80
DYN Dyne Therapeutics	3.2244 of 5 stars	$23.44 +2.6%	$34.17 +45.7%	+173.6%	$3.92B	N/A	N/A	100
CPRX Catalyst Pharmaceuticals	3.8785 of 5 stars	$31.48 -0.1%	$32.00 +1.7%	+44.3%	$3.85B	$588.99M	18.09	80
BEAM Beam Therapeutics	3.3778 of 5 stars	$37.37 +5.8%	$46.83 +25.3%	+46.5%	$3.83B	$139.74M	N/A	510	Gap Up
RCUS Arcus Biosciences	3.891 of 5 stars	$30.26 +0.9%	$35.10 +16.0%	+200.8%	$3.82B	$247M	N/A	500	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DBVT) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DBV Technologies (DBVT) Competitors

DBVT vs. DYN, CPRX, BEAM, RCUS, and RLAY

How does DBV Technologies compare to Dyne Therapeutics?

Summary

How does DBV Technologies compare to Catalyst Pharmaceuticals?

Summary

How does DBV Technologies compare to Beam Therapeutics?

Summary

How does DBV Technologies compare to Arcus Biosciences?

Summary

How does DBV Technologies compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DBV Technologies (DBVT) Competitors

DBVT vs. DYN, CPRX, BEAM, RCUS, and RLAY

How does DBV Technologies compare to Dyne Therapeutics?

Do analysts recommend DBVT or DYN?

Do insiders & institutionals believe in DBVT or DYN?

Does the media favor DBVT or DYN?

Is DBVT or DYN more profitable?

Which has higher earnings & valuation, DBVT or DYN?

Which has more risk and volatility, DBVT or DYN?

Summary

How does DBV Technologies compare to Catalyst Pharmaceuticals?

Is CPRX or DBVT more profitable?

Do analysts prefer CPRX or DBVT?

Does the media refer more to CPRX or DBVT?

Which has higher valuation & earnings, CPRX or DBVT?

Do insiders and institutionals hold more shares of CPRX or DBVT?

Which has more risk and volatility, CPRX or DBVT?

Summary

How does DBV Technologies compare to Beam Therapeutics?

Do analysts recommend DBVT or BEAM?

Which has higher earnings and valuation, DBVT or BEAM?

Is DBVT or BEAM more profitable?

Do insiders and institutionals believe in DBVT or BEAM?

Which has more volatility and risk, DBVT or BEAM?

Does the media prefer DBVT or BEAM?

Summary

How does DBV Technologies compare to Arcus Biosciences?

Is DBVT or RCUS more profitable?

Do analysts prefer DBVT or RCUS?

Do institutionals and insiders believe in DBVT or RCUS?

Does the media prefer DBVT or RCUS?

Which has stronger earnings & valuation, DBVT or RCUS?

Which has more volatility & risk, DBVT or RCUS?

Summary

How does DBV Technologies compare to Relay Therapeutics?

Is RLAY or DBVT more profitable?

Does the media favor RLAY or DBVT?

Do insiders & institutionals have more ownership in RLAY or DBVT?

Which has preferable valuation & earnings, RLAY or DBVT?

Which has more risk and volatility, RLAY or DBVT?

Do analysts recommend RLAY or DBVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools